Answers are grounded in this paper and cite their sources.
Shows upregulation of circulating miR-132 and miR-152 in heart failure, suggesting these serum microRNAs may serve as biomarkers for cardiac pathology.
MicroRNAs (miRs) are emerging targets for the diagnosis, prognosis and treatment of heart failure (HF). Accumulated evidence showed that microRNA-132 (miR-132) and microRNA-152 (miR-152) play critical roles in the development of multiple pathological processes of the heart. Although their upregulations have been detected in the failing hearts of humans and animal models, little is known about the circulating levels of miR-132 and miR-152 in patients with HF.
No takes yet. Share an insight, caveat, or question.
Vu et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: